Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.58Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasizes multiple encouraging clinical signals for evorpocept (EVO) — including biomarker‑driven responses across gastric, breast and NHL settings — and steady clinical progress for the ALX 2004 ADC. The company materially strengthened its balance sheet with a recent equity financing providing runway through 2028 and reduced quarterly operating losses year‑over‑year. Key risks remain: several datasets are early and small, biomarker cut‑point and prevalence uncertainty prompted an upsizing of ASPEN, safety and therapeutic window for the ADC must be confirmed clinically, and several important readouts are still 12–18 months away. Overall, positive clinical validation and a strong financing event outweigh the staging‑related uncertainties.Company Guidance
Robust clinical data validating CD47 biomarker
Multiple independent datasets (gastric, breast, NHL) demonstrate CD47 as a predictive biomarker for evorpocept (EVO). In HER2-positive gastric cancer CD47-high subgroup, response rate was 65% vs 26% control (delta ~39%), median PFS 18.4 vs 7.0 months (HR 0.39), median OS 17 vs ~10 months (HR 0.7), and median duration of response >2 years (>3x control). In a small HER2-positive breast combo cohort (n=9 confirmed HER2), response rate was 56% with median PFS 7.4 months; responders were predominantly CD47 overexpressors.
Strong activity in hematologic malignancies
In treatment‑naive, first‑line indolent non‑Hodgkin’s lymphoma patients treated with EVO + R‑squared, complete response (CR) rate reached 92%, described as almost double the CR rate seen with R‑squared alone, supporting broad potential of EVO in heme malignancies when combined with Fc‑active antibodies.
ALX 2004 (EGFR ADC) progressing through dose escalation
ALX 2004 cleared the first two dose cohorts and is dosing at 4 mg/kg in phase 1 (dose escalation + expansion). Preclinical data show potent, dose‑dependent antitumor activity across EGFR expression levels and relevant mutations, with no EGFR‑related skin toxicity or interstitial lung disease seen in GLP nonhuman primate tox studies. Full dose‑escalation safety data expected in 2H 2026.
Large financing strengthens balance sheet and runway
Completed an equity financing with gross proceeds of $150,000,000 and net proceeds of $140,400,000. Company had $48.3M cash & investments at 12/31/2025 pre‑financing and states the post‑financing cash position is sufficient to fund operations through 2028, enabling delivery of multiple near‑term data readouts.
Operational focus and clear near‑term milestones
Management prioritizing execution on two lead programs (EVO and ALX 2004). Key guided milestones: full biomarker analysis from the danitatumab combo at ESMO Breast (May 2026), ALX 2004 dose‑escalation safety data (2026), and top‑line ASPEN breast data from 80 patients (mid‑2027).
Reduced quarterly GAAP net loss year‑over‑year
GAAP net loss for the quarter was $22.8M ($0.42 per share) vs $29.2M ($0.55) year‑ago — a decrease of approximately 22% in dollars and ~24% on a per‑share basis, attributed to lower stock compensation, personnel costs, and reduced preclinical spending after pipeline prioritization.
Expansion and biomarker‑driven refinement of ASPEN‑9
Phase 2 ASPEN‑9 breast trial upsized from 80 to up to 120 patients and primary endpoint updated to response rate in CD47‑high patients to increase power for selecting a predictive CD47 cut point; top‑line readout for 80 patients still guided to mid‑2027.
ALXO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALXO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 27, 2026 | $2.35 | $2.11 | -10.21% |
Nov 07, 2025 | $1.18 | $1.38 | +16.95% |
Aug 12, 2025 | $0.62 | $0.66 | +6.45% |
May 08, 2025 | $0.48 | $0.46 | -4.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ALX Oncology Holdings (ALXO) report earnings?
ALX Oncology Holdings (ALXO) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is ALX Oncology Holdings (ALXO) earnings time?
ALX Oncology Holdings (ALXO) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALXO EPS forecast?
ALXO EPS forecast for the fiscal quarter 2026 (Q1) is -0.25.